查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026771

神經內分泌腫瘤治療市場預測至2034年－按服務、動物模型、模型類型、最終用戶和地區分類的全球分析

Neuroendocrine Tumor Treatment Market Forecasts to 2034 - Global Analysis By Service, Animal Model, Model Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球神經內分泌腫瘤治療市場規模將達到 40.7 億美元，在預測期內將以 15.7% 的複合年成長率成長，到 2034 年將達到 128.675 億美元。

神經內分泌腫瘤的治療涉及多種醫療干預措施，旨在控制神經內分泌腫瘤（NETs）。 NETs是一組起源於神經內分泌細胞的罕見腫瘤，種類繁多。雖然這些腫瘤可發生於多個器官，但最常涉及胰臟和消化器官系統。

根據美國國家轉化科學促進中心 (NCATS) 下屬的遺傳和罕見疾病資訊中心 2021 年 11 月更新的數據，美國約有 3,000 至 30,000 人患有類癌腫瘤，這種腫瘤通常發生在胃腸道或肺部。

拓展神經內分泌腫瘤的治療方法

為了因應患者數量的不斷成長，製藥和生物技術公司正加大研發投入，以期透過早期診斷改善患者預後並實現適當的干涉。診斷技術的進步、公眾意識的提高、生活方式的改變，以及基於分子譜分析的精準醫療等諸多因素，正在推動個人化治療策略的實施，進而促進市場擴張。

高昂的醫療費用

處方藥、醫療程序、住院治療和後續觀察的費用可能使患者難以獲得昂貴的治療，尤其是那些經濟拮据或保險不足的患者。神經內分泌腫瘤的高昂治療費用使得醫療系統難以充分資助這些治療，這可能會限制患者獲得這些必要療法的機會和負擔能力。此外，保險覆蓋不足和高額自付費用進一步阻礙了患者獲得最佳治療。

研發進度

分子譜分析已成為神經內分泌腫瘤（NET）研究的關鍵環節，能夠識別與這些腫瘤相關的特定生物標記和基因突變。這些發現促成了多種創新治療方法的問世，例如生長抑制素類似物、mTOR抑制劑和胜肽受體放射性核種療法（PRRT）。此外，持續的科學發現正加深我們對分子機制和遺傳因素的理解，最終改善患者預後，擴大可用治療方法的範圍，推動市場成長。

意識水平低

神經內分泌腫瘤（NETs）相對罕見，且臨床表現多種多樣，因此難以發現。許多醫療專業人員可能對這類腫瘤認知不足，進而導致診斷延遲或誤診。此外，對NETs缺乏了解也可能導致患者誤解自身症狀，延誤就醫。這種認知不足的情況在整個醫療界普遍存在，可能導致NET病例的治療不足。

新冠疫情的感染疾病

新冠疫情對神經內分泌腫瘤治療市場造成了負面影響。封鎖措施和醫療機構容量限制導致神經內分泌腫瘤的檢測和治療延誤，影響了患者的治療效果。創新藥物的臨床試驗受到限制，資源重新分配和重點轉向應對疫情，加劇了醫療服務能力的不足。此外，對免疫抑制的擔憂以及醫療系統的財政壓力也影響了患者開始和繼續治療的意願，逐漸抑制了市場規模的成長。

在預測期內，化療領域預計將成為規模最大的領域。

化療預計將佔據最大的市場。當手術或其他治療方法無效時，通常會考慮化療，尤其是在神經內分泌腫瘤（NETs）的晚期或轉移階段。雖然化療有助於控制症狀、抑制腫瘤生長並改善患者的生活品質，但它並非總是根治性疾病。此外，標靶治療和個人化化療方案的研究正在進行，旨在減少副作用並改善神經內分泌腫瘤患者的治療效果，這推動了該領域的成長。

預計在預測期內，胰臟神經內分泌腫瘤領域的複合年成長率將最高。

在預測期內，胰臟神經內分泌腫瘤預計將呈現最高的複合年成長率。這些腫瘤起源於胰臟內分泌細胞，由於其獨特的特徵，需要特殊的治療方案。胰臟神經內分泌腫瘤（pNETs）的治療採用多學科綜合策略，需考慮腫瘤分級、分期和功能等因素。此外，對於進行性或轉移性pNETs，生長抑制素類似物（可控制荷爾蒙相關症狀並抑制促進腫瘤生長的路徑）正被視為治療選擇，這推動了該細分市場的成長。

市佔率最大的地區：

由於PET- 電腦斷層掃描和分子譜分析等先進診斷工具的運用，神經內分泌腫瘤（NETs）的早期檢測和鑑別診斷能力得到提升，亞太地區在預測期內佔據了最大的市場佔有率。標靶治療和免疫療法正日益受到關注，為患者提供更有效、更個人化的治療選擇。此外，醫療相關人員、政府部門和製藥公司之間的合作對於彌合現有差距、全面提升NET治療水平至關重要，這將推動該地區的市場成長。

複合年成長率最高的地區：

由於政府的醫療保健政策和保險覆蓋範圍顯著影響患者獲得治療的機會，預計北美地區在預測期內將實現最高的複合年成長率。禮來公司、諾華公司、和記黃埔醫藥有限公司和輝瑞公司等領先企業在該地區擁有有利的營運環境，這得益於該地區嚴格的監管以及公共和私人對醫療保健和研發的大規模投資。美國食品藥物管理局（FDA）等監管機構在核准藥品和治療器材方面發揮核心作用，確保其安全性和有效性，從而推動了該地區的成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球神經內分泌腫瘤治療市場：依療法分類

  • 化療
  • 標靶治療
  • 生長抑制素類似物
  • 免疫療法
  • 其他治療方法

第6章 全球神經內分泌腫瘤治療市場：依疾病適應症分類

  • 胰臟神經內分泌腫瘤
  • 肺神經內分泌腫瘤
  • 胃腸道神經內分泌腫瘤
  • 其他疾病指徵

第7章 全球神經內分泌腫瘤治療市場：依給藥途徑分類

  • 腸外
  • 口服

第8章：全球神經內分泌腫瘤治療市場：依發生部位分析

  • 冒號
  • 肺
  • 小腸
  • 胰臟
  • 其他身體部位分析

第9章 全球神經內分泌腫瘤治療市場：依最終用戶分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 其他最終用戶

第10章 全球神經內分泌腫瘤治療市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第11章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • Novartis AG
  • Exelixis, Inc.
  • Boehringer Ingelheim International GmbH
  • Tarveda Therapeutics
  • Dauntless Pharmaceuticals
  • Hutchison MediPharma Limited
  • AVEO Oncology
  • Pfizer Inc.
  • Ipsen Pharma
  • Progenics Pharmaceuticals, Inc.
  • Eli Lilly & Company
  • Lantheus Holdings, Inc.
  • Jubilant Life Sciences Ltd.
Product Code: SMRC24607

According to Stratistics MRC, the Global Neuroendocrine Tumor Treatment Market is accounted for $4007.0 million in 2026 and is expected to reach $12867.5 million by 2034 growing at a CAGR of 15.7% during the forecast period. Neuroendocrine tumor treatment encompasses a range of medical interventions aimed at managing neuroendocrine tumors (NETs), a diverse group of rare neoplasms that arise from neuroendocrine cells. These tumors can develop in a number of organs, although they most frequently affect the pancreas and digestive system.

According to the National Center for Advancing Translational Sciences - Genetic and Rare Diseases Information Center data updated in November 2021, there were around 3,000 to 30,000 people in the United States affected by carcinoid tumor, which usually develops in the gastrointestinal tract or the lungs.

Market Dynamics:

Driver:

Expansion of neuroendocrine tumor treatments

The growing number of patients has encouraged pharmaceutical and biotechnology businesses to spend money on research and development for better patient outcomes and appropriate interventions resulting from early diagnosis. Several factors including improved diagnostic techniques, greater awareness, and changes in lifestyle, precision medicine, guided by molecular profiling, allows for personalized therapeutic strategies, which are driving this market size.

Restraint:

High treatment costs

Patients may find it difficult to receive high-cost treatments, especially if they have limited financial resources or insufficient insurance, due to the expense of prescription drugs, medical procedures, hospital stays, and follow-up care. The high expense of treating neuroendocrine tumors may make it difficult for healthcare systems to devote enough funding, which could restrict the accessibility and affordability of these essential treatments. Furthermore, insurance coverage gaps and high out-of-pocket expenses further impede patient access to optimal treatment.

Opportunity:

Advancements in research developments

Molecular profiling has emerged as a key aspect of NET research, enabling the identification of specific biomarkers and genetic mutations associated with these tumors. These discoveries have led to the introduction of innovative treatment options such as somatostatin analogs, mTOR inhibitors, and peptide receptor radionuclide therapy (PRRT). Moreover, the ongoing scientific discoveries contribute to a deeper understanding of molecular mechanisms and genetic factors, ultimately enhancing patient outcomes and expanding the range of available treatments, thereby driving market growth.

Threat:

Lack of awareness

Neuroendocrine tumors (NETs) are difficult to detect since they are comparatively uncommon and present with a variety of symptoms. These tumors may not be well known to many medical professionals, which could cause delayed or incorrect diagnoses. Additionally, lack of knowledge on NETs, causes them to incorrectly interpret symptoms and delay seeking medical attention. This lack of awareness also extends to the broader medical community, potentially leading to suboptimal management of NET cases.

Covid-19 Impact

The market for neuroendocrine tumor treatments was adversely affected by the COVID-19 pandemic. Patient outcomes were impacted by delayed neuroendocrine tumor detection and treatment as a result of lockdowns and restricted capacity in healthcare facilities. Clinical trials for innovative medicines were restricted, and the availability of healthcare services was stretched due to the reallocation of resources and attention toward addressing the pandemic. Furthermore, concerns about immunosuppression and financial limitations on healthcare systems also affected the willingness to start or maintain therapy, gradually hindering the market size.

The chemotherapy segment is expected to be the largest during the forecast period

The chemotherapy segment is estimated to hold the largest share. Chemotherapy is typically considered in cases where surgery and other treatments are less effective, often in the advanced or metastatic stages of NETs. Chemotherapy can help control symptoms, reduce tumor growth, and enhance the patient's quality of life, but treatment is not always curative. Moreover, targeted and individualized chemotherapy regimens are being investigated in order to reduce side effects and improve treatment outcomes for people with neuroendocrine tumors, which is boosting this segment's expansion.

The pancreatic neuroendocrine tumor segment is expected to have the highest CAGR during the forecast period

The pancreatic neuroendocrine tumor segment is anticipated to have the highest CAGR during the forecast period. These tumors arise from the endocrine cells of the pancreas, and their distinct characteristics necessitate specialized treatment considerations. Treatment approaches for pNETs involve a multidisciplinary strategy, considering factors such as tumor grade, stage, and functionality. Additionally, for advanced or metastatic pNETs, therapeutic options include somatostatin analogs, which help control hormone-related symptoms and inhibit pathways promoting tumor growth, which are driving this segment's growth.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to advanced diagnostic tools, such as PET-CT scans and molecular profiling that have enhanced the early detection and characterization of neuroendocrine tumors. Targeted therapies and immunotherapies have gained prominence, offering more effective and personalized treatment options. Furthermore, collaborative efforts among healthcare stakeholders, government bodies, and pharmaceutical companies are crucial to addressing these disparities and enhancing the overall NET treatment, which is driving this region's growth.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to government healthcare policies and insurance coverage that significantly influence patient access to these treatments. Key players such as Eli Lilly & Company, Novartis AG, Hutchison MediPharma Limited, and Pfizer Inc. are developing in a favorable environment due to the region's strict regulations and large public and private investments in healthcare and research. Regulatory bodies like the FDA (Food and Drug Administration) play a central role in drug and treatment device approvals, ensuring safety and efficacy, which are propelling this region's expansion.

Key players in the market

Some of the key players in the Neuroendocrine Tumor Treatment Market include Novartis AG, Exelixis, Inc., Boehringer Ingelheim International GmbH, Tarveda Therapeutics, Dauntless Pharmaceuticals, Hutchison MediPharma Limited, AVEO Oncology, Pfizer Inc., Ipsen Pharma, Progenics Pharmaceuticals, Inc., Eli Lilly & Company, Lantheus Holdings, Inc. and Jubilant Life Sciences Ltd.

Key Developments:

In October 2023, Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.

In August 2023, Novartis announced that it has completed its acquisition of Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases.

In July 2023, Eli Lilly and Company and Versanis Bio announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.

In July 2023, Flagship Pioneering, Inc. and Pfizer Inc. announced the companies have partnered to create a new pipeline of innovative medicines.

Therapies Covered:

  • Chemotherapy
  • Targeted Therapy
  • Somatostatin Analogues
  • Immunotherapy
  • Other Therapies

Disease Indications Covered:

  • Pancreatic Neuroendocrine Tumor
  • Lung Neuroendocrine Tumor
  • Gastrointestinal Neuroendocrine Tumor
  • Other Disease Indications

Route of Administrations Covered:

  • Parenteral
  • Oral

Site Analysis Covered:

  • Colon
  • Lungs
  • Small Intestine
  • Pancreas
  • Other Site Analysis

End Users Covered:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neuroendocrine Tumor Treatment Market, By Therapy

  • 5.1 Introduction
  • 5.2 Chemotherapy
  • 5.3 Targeted Therapy
  • 5.4 Somatostatin Analogues
  • 5.5 Immunotherapy
  • 5.6 Other Therapies

6 Global Neuroendocrine Tumor Treatment Market, By Disease Indication

  • 6.1 Introduction
  • 6.2 Pancreatic Neuroendocrine Tumor
  • 6.3 Lung Neuroendocrine Tumor
  • 6.4 Gastrointestinal Neuroendocrine Tumor
  • 6.5 Other Disease Indications

7 Global Neuroendocrine Tumor Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Parenteral
  • 7.3 Oral

8 Global Neuroendocrine Tumor Treatment Market, By Site Analysis

  • 8.1 Introduction
  • 8.2 Colon
  • 8.3 Lungs
  • 8.4 Small Intestine
  • 8.5 Pancreas
  • 8.6 Other Site Analysis

9 Global Neuroendocrine Tumor Treatment Market, By End User

  • 9.1 Introduction
  • 9.2 Hospital Pharmacy
  • 9.3 Online Pharmacy
  • 9.4 Retail Pharmacy
  • 9.5 Other End Users

10 Global Neuroendocrine Tumor Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Novartis AG
  • 12.2 Exelixis, Inc.
  • 12.3 Boehringer Ingelheim International GmbH
  • 12.4 Tarveda Therapeutics
  • 12.5 Dauntless Pharmaceuticals
  • 12.6 Hutchison MediPharma Limited
  • 12.7 AVEO Oncology
  • 12.8 Pfizer Inc.
  • 12.9 Ipsen Pharma
  • 12.10 Progenics Pharmaceuticals, Inc.
  • 12.11 Eli Lilly & Company
  • 12.12 Lantheus Holdings, Inc.
  • 12.13 Jubilant Life Sciences Ltd.

List of Tables

  • Table 1 Global Neuroendocrine Tumor Treatment Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2023-2034) ($MN)
  • Table 3 Global Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 4 Global Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2023-2034) ($MN)
  • Table 5 Global Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2023-2034) ($MN)
  • Table 6 Global Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2023-2034) ($MN)
  • Table 7 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2023-2034) ($MN)
  • Table 8 Global Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2023-2034) ($MN)
  • Table 9 Global Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 10 Global Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 11 Global Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 12 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2023-2034) ($MN)
  • Table 13 Global Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 14 Global Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 15 Global Neuroendocrine Tumor Treatment Market Outlook, By Oral (2023-2034) ($MN)
  • Table 16 Global Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2023-2034) ($MN)
  • Table 17 Global Neuroendocrine Tumor Treatment Market Outlook, By Colon (2023-2034) ($MN)
  • Table 18 Global Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2023-2034) ($MN)
  • Table 19 Global Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2023-2034) ($MN)
  • Table 20 Global Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2023-2034) ($MN)
  • Table 21 Global Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2023-2034) ($MN)
  • Table 22 Global Neuroendocrine Tumor Treatment Market Outlook, By End User (2023-2034) ($MN)
  • Table 23 Global Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 24 Global Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 25 Global Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 26 Global Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 27 North America Neuroendocrine Tumor Treatment Market Outlook, By Country (2023-2034) ($MN)
  • Table 28 North America Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2023-2034) ($MN)
  • Table 29 North America Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 30 North America Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2023-2034) ($MN)
  • Table 31 North America Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2023-2034) ($MN)
  • Table 32 North America Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2023-2034) ($MN)
  • Table 33 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2023-2034) ($MN)
  • Table 34 North America Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2023-2034) ($MN)
  • Table 35 North America Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 36 North America Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 37 North America Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 38 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2023-2034) ($MN)
  • Table 39 North America Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 40 North America Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 41 North America Neuroendocrine Tumor Treatment Market Outlook, By Oral (2023-2034) ($MN)
  • Table 42 North America Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2023-2034) ($MN)
  • Table 43 North America Neuroendocrine Tumor Treatment Market Outlook, By Colon (2023-2034) ($MN)
  • Table 44 North America Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2023-2034) ($MN)
  • Table 45 North America Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2023-2034) ($MN)
  • Table 46 North America Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2023-2034) ($MN)
  • Table 47 North America Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2023-2034) ($MN)
  • Table 48 North America Neuroendocrine Tumor Treatment Market Outlook, By End User (2023-2034) ($MN)
  • Table 49 North America Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 50 North America Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 51 North America Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 52 North America Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 53 Europe Neuroendocrine Tumor Treatment Market Outlook, By Country (2023-2034) ($MN)
  • Table 54 Europe Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2023-2034) ($MN)
  • Table 55 Europe Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 56 Europe Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2023-2034) ($MN)
  • Table 57 Europe Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2023-2034) ($MN)
  • Table 58 Europe Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2023-2034) ($MN)
  • Table 59 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2023-2034) ($MN)
  • Table 60 Europe Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2023-2034) ($MN)
  • Table 61 Europe Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 62 Europe Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 63 Europe Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 64 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2023-2034) ($MN)
  • Table 65 Europe Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 66 Europe Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 67 Europe Neuroendocrine Tumor Treatment Market Outlook, By Oral (2023-2034) ($MN)
  • Table 68 Europe Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2023-2034) ($MN)
  • Table 69 Europe Neuroendocrine Tumor Treatment Market Outlook, By Colon (2023-2034) ($MN)
  • Table 70 Europe Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2023-2034) ($MN)
  • Table 71 Europe Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2023-2034) ($MN)
  • Table 72 Europe Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2023-2034) ($MN)
  • Table 73 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2023-2034) ($MN)
  • Table 74 Europe Neuroendocrine Tumor Treatment Market Outlook, By End User (2023-2034) ($MN)
  • Table 75 Europe Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 76 Europe Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 77 Europe Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 78 Europe Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 79 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Country (2023-2034) ($MN)
  • Table 80 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2023-2034) ($MN)
  • Table 81 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 82 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2023-2034) ($MN)
  • Table 83 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2023-2034) ($MN)
  • Table 84 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2023-2034) ($MN)
  • Table 85 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2023-2034) ($MN)
  • Table 86 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2023-2034) ($MN)
  • Table 87 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 88 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 89 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 90 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2023-2034) ($MN)
  • Table 91 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 92 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 93 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Oral (2023-2034) ($MN)
  • Table 94 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2023-2034) ($MN)
  • Table 95 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Colon (2023-2034) ($MN)
  • Table 96 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2023-2034) ($MN)
  • Table 97 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2023-2034) ($MN)
  • Table 98 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2023-2034) ($MN)
  • Table 99 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2023-2034) ($MN)
  • Table 100 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By End User (2023-2034) ($MN)
  • Table 101 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 102 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 103 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 104 Asia Pacific Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 105 South America Neuroendocrine Tumor Treatment Market Outlook, By Country (2023-2034) ($MN)
  • Table 106 South America Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2023-2034) ($MN)
  • Table 107 South America Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 108 South America Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2023-2034) ($MN)
  • Table 109 South America Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2023-2034) ($MN)
  • Table 110 South America Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2023-2034) ($MN)
  • Table 111 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2023-2034) ($MN)
  • Table 112 South America Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2023-2034) ($MN)
  • Table 113 South America Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 114 South America Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 115 South America Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 116 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2023-2034) ($MN)
  • Table 117 South America Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 118 South America Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 119 South America Neuroendocrine Tumor Treatment Market Outlook, By Oral (2023-2034) ($MN)
  • Table 120 South America Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2023-2034) ($MN)
  • Table 121 South America Neuroendocrine Tumor Treatment Market Outlook, By Colon (2023-2034) ($MN)
  • Table 122 South America Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2023-2034) ($MN)
  • Table 123 South America Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2023-2034) ($MN)
  • Table 124 South America Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2023-2034) ($MN)
  • Table 125 South America Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2023-2034) ($MN)
  • Table 126 South America Neuroendocrine Tumor Treatment Market Outlook, By End User (2023-2034) ($MN)
  • Table 127 South America Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 128 South America Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 129 South America Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 130 South America Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 131 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Country (2023-2034) ($MN)
  • Table 132 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Therapy (2023-2034) ($MN)
  • Table 133 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 134 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Targeted Therapy (2023-2034) ($MN)
  • Table 135 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Somatostatin Analogues (2023-2034) ($MN)
  • Table 136 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Immunotherapy (2023-2034) ($MN)
  • Table 137 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Therapies (2023-2034) ($MN)
  • Table 138 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Disease Indication (2023-2034) ($MN)
  • Table 139 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Pancreatic Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 140 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Lung Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 141 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Gastrointestinal Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 142 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Disease Indications (2023-2034) ($MN)
  • Table 143 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 144 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 145 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Oral (2023-2034) ($MN)
  • Table 146 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Site Analysis (2023-2034) ($MN)
  • Table 147 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Colon (2023-2034) ($MN)
  • Table 148 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Lungs (2023-2034) ($MN)
  • Table 149 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Small Intestine (2023-2034) ($MN)
  • Table 150 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Pancreas (2023-2034) ($MN)
  • Table 151 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other Site Analysis (2023-2034) ($MN)
  • Table 152 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By End User (2023-2034) ($MN)
  • Table 153 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 154 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 155 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 156 Middle East & Africa Neuroendocrine Tumor Treatment Market Outlook, By Other End Users (2023-2034) ($MN)